PILA PHARMA AB Logo

PILA PHARMA AB

Clinical-stage biopharma developing a first-in-class oral drug for diabetes and obesity.

PILA | ST

Overview

Corporate Details

ISIN(s):
SE0015988274
LEI:
6488Z7WG18Q0ZN0V0262
Country:
Sweden
Address:
Norra Vallgatan 72, 211 22 Malmö
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

PILA PHARMA AB is a clinical-stage biopharmaceutical company focused on developing a potential first-in-class oral treatment for metabolic diseases, primarily type 2 diabetes and obesity. The company's lead candidate, XEN-D0501, is a TRPV1 antagonist, representing a novel therapeutic approach with a different mechanism of action compared to mainstream treatments. The company's strategy emphasizes the development of a convenient oral tablet to address the large global patient population. PILA PHARMA is actively advancing its clinical program, with a recent strategic focus on dedicated obesity studies aimed at generating a comprehensive data package to facilitate future partnerships.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PILA PHARMA AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PILA PHARMA AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PILA PHARMA AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

OncoZenge AB Logo
Developing a non-opioid lozenge for oral pain relief in cancer patients.
Sweden
ONCOZ
OPTIBIOTIX HEALTH PLC Logo
Develops microbiome-modulating ingredients and supplements to manage chronic lifestyle diseases.
United Kingdom
OPTI
OXFORD BIODYNAMICS PLC Logo
Develops precision blood tests using 3D genomics for cancer diagnosis and therapy guidance.
United Kingdom
OBD
Pharnext Logo
France
ALPHA
PHYSIOMICS PLC Logo
De-risks oncology drug development for pharma/biotech using modeling and simulation.
United Kingdom
PYC
POOLBEG PHARMA PLC Logo
AI-led biopharma developing drugs for high-need diseases like CRS and metabolic disorders.
United Kingdom
POLB
PROTEOME SCIENCES PLC Logo
CRO providing proteomics services & TMT® tags to biopharma for drug discovery & biomarkers.
United Kingdom
PRM
PROVEXIS PLC Logo
Develops & licenses Fruitflow®, a patented ingredient for heart health in food & supplements.
United Kingdom
PXS
Develops uncopiable atomic fingerprints for anti-counterfeiting, verifiable by smartphone.
United Kingdom
QUBE
QUANTUM BLOCKCHAIN TECHNOLOGIES PLC Logo
R&D firm using AI and quantum computing to create efficient technologies for Bitcoin mining.
United Kingdom
QBT

Talk to a Data Expert

Have a question? We'll get back to you promptly.